TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07779408: A Phase 1/2, Parallel, Observer-blind Study to Assess the Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Abov

Sponsor: Sanofi · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 640 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$9,384,000

Rescue Site Savings

+$6,187,575

Unlock Full NCT07779408 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07779408 Rescue Dossier →